Showing 7971-7980 of 8822 results for "".
- Botanical Dermatology Brand Kamedis Forms U.S. Medical Advisory Boardhttps://practicaldermatology.com/news/botanical-dermatology-brand-kamedis-forms-us-medical-advisory-board/2457834/Israeli-based Kamedis announced the formation of a U.S. medical advisory board. The members include: Zoe Draelos, MD, FAAD, a clinical and research dermatologist with a private solo practice in High Point, NC, who is also a Consulting Professo
- YouTube AD Videos Unreliablehttps://practicaldermatology.com/news/youtube-ad-videos-unreliable/2457835/Perhaps no surprise to dermatologists, new research reveals that one-third of YouTube videos about atopic dermatitis contain misleading information. That’s according to researchers from the University of Texas Health Science Center in Houston who reviewed 128 YouTub
- ALASTIN Adds to Board of Directorshttps://practicaldermatology.com/news/alastin-adds-to-board-of-directors/2457837/Ann Rhoads and Elisabeth Sandoval are now members of ALASTIN Skincare, Inc’s Board of Directors. Ms. Rhoads is a healthcare finance executive with more than 25 years of experience which includes roles as Chief Financial Officer of
- Colorescience Adds to Board of Directorshttps://practicaldermatology.com/news/colorescience-adds-to-board-of-directors/2457838/David Olsen and Ty Stiklorius are joining Colorescience’s Board of Directors. David Olsen is the Chief Executive Officer (CEO) of Cos Bar. Since joining Cos Bar in February 2016, he has worked to grow the company while
- First Patient Dosed in Proof-of-Concept Trial of Topical by Design JAK Inhibitor SNA-125 for Atopic Dermatitishttps://practicaldermatology.com/news/first-patient-dosed-in-proof-of-concept-trial-of-topical-by-design-jak-inhibitor-sna-125-for-atopic-dermatitis/2457839/The first patient has been dosed in Sienna Biopharmaceuticals, Inc.'s Phase 1/2 proof-of-concept clinical trial of topical product candidate SNA-125 in the treatment of atopic dermatitis and the associated pruritus. SNA-125 is designed to inhibit Janus kinase 3, or JAK3, and tropomyosin recep
- White Paper: It's Time to Start Prescribing Biosimilarshttps://practicaldermatology.com/news/white-paper-its-time-to-start-prescribing-biosimilars/2457843/The American College of Rheumatology’s new white paper, “The Science Behind Biosimilars — Entering a New Era of Biologic Therapy,
- Novartis' Xolair Recommended in New Global Chronic Urticaria Guidelinehttps://practicaldermatology.com/news/novartis-xolair-recommended-in-new-global-chronic-urticaria-guideline/2457849/A new global guideline on chronic urticaria (CU) recommends Xolair (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU), for patients who are not responding to antihistamines. Xolair is the only licensed treatment option for CSU, a type of CU, for pat
- Dermira: Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpointshttps://practicaldermatology.com/news/dermira-two-phase-3-trials-evaluating-olumacostat-glasaretil-in-patients-with-acne-vulgaris-did-not-meet-co-primary-endpoints/2457852/Dermira, Inc.'s investigational treatment olumacostat glasaretil (formerly DRM01) did not meet the co-primary endpoints in its two Phase 3 pivotal trials (CLAREOS-1 and CLAREOS-2) in patients ages nine years and older with moderate-to-severe acne vulgaris. “We are surprised and
- Botox Biosimilar in the Workshttps://practicaldermatology.com/news/botox-biosimilar-in-the-works/2457853/Mylan N.V. and Revance Therapeutics, Inc. are partnering to develop a biosimilar to BOTOX® (onabotulinumtoxinA). "We have reviewed the work done to date by Revance and we are extremely excited and confident
- Burt's Bees Nature-Based Sensitive Skin Regimen Trumps Dermatologist-recommended Regimenhttps://practicaldermatology.com/news/burts-bees-nature-based-sensitive-skin-regimen-trumps-dermatologist-recommended-regimen/2457860/Burt's Bees nature-based sensitive line outperformed a dermatologist-recommended synthetic control regimen in a study of 120 people with clinically diagnosed sensitive skin from rosacea, atopic dermatitis/eczema, or cosmetic intolerance. The nat